Reviews Write New Review
Location
Booking Fee
Fee: $##,###Get Pricing
Virtual Fee: $##,###Get Pricing
[email protected]
Troy Townsend Rohn
Professor, Neuroscientist & Director of Preclinical Studies at Cognigenics; Expert on Alzheimer's Disease
Dr. Troy T. Rohn is a distinguished speaker, renowned for his expertise in the fields of neurology, Alzheimer's disease, and mental health. With a passion for unraveling the mysteries of the human brain, Dr. Rohn's insightful presentations shed light on complex scientific topics in an engaging and accessible manner. Dr. Rohn's impact extends beyond the lecture hall, as he has shared his insights through numerous talks on Alzheimer's disease and related subjects. His informative TEDx talk on Alzheimer's disease underscored his dedication to raising public awareness and fostering a deeper understanding of this critical issue.
Dr. Rohn's influence is not limited to academia, as he has collaborated with diverse corporate clients seeking to leverage his expertise in neuroscience and mental health. His dynamic presentations have illuminated the potential of cutting-edge technologies like CRISPR/Cas9 in addressing mental health challenges.
Speech Topics
The application of CRISPR to treat neurological disorders
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genetic technology that allows for precise editing of DNA. It functions like molecular scissors, cutting DNA at a specific location and allowing researchers to add, remove, or replace specific sections of genetic code. This technology has immense potential for treating a wide range of genetic diseases. By using CRISPR to target and modulate specific neuronal receptors known to be associated with mental health disorders, we can vastly improve overall cognitive health and wellbeing and potentially eradicate these conditions.
Attendee Results: By covering this topic, Attendees will come away with a comprehensive understanding of the current advancements, challenges, and future prospects of using CRISPR to address anxiety, depression, and memory loss. This will empower Attendees to engage in informed discussions, consider potential applications, and contribute to the ongoing research in this fascinating and evolving field.
Early-onset Alzheimer's: should you worry?
Alzheimer’s is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, leading to cognitive impairment that severely affects daily living. People frequently ask if they might be afflicted with the disease if a grandparent had Alzheimer’s. This presentation will focus on understanding the difference between early-onset vs. late-onset Alzheimer's and the prevalence of each.
Attendee Results: The Attendee Results would likely reflect a better understanding between the two major forms of Alzheimer's disease as well as the prevalence of each form in the United States. In addition, Attendees will understand the critical need for disease-modifying treatments for this devastating disease.
Should I be tested for Alzheimer's disease?
Currently, 5 million Americans suffer form Alzheimer's disease and it is currently the 6th leading cause of death. Understanding the disease process and genetic risk factors identified is critical for understanding how a diagnosis is made.
Attendee Results: The Attendee Results would likely reflect a better understanding of what are the most important genetic risk factors for Alzheimer's and what are lifestyle changes that can be made to build our mind's resilience to this devastating disease.
Harnessing the power of the genome editing tool, CRISPR, to treat anxiety
250 million people worldwide suffer from severe and chronic anxiety disorders, and 30% do not respond to current treatments such as Zoloft and Lexapro. In this presentation, recent data will illustrate how a novel CRISPR/Cas9 gene-editing delivery system can bypass the blood-brain barrier and modulate neuronal serotonin receptor pathways to lower anxiety in mice. Intranasal delivery of CRISPR/Cas9 therapeutics to the brain may help patients who exhibit treatment-resistant anxiety.
Attendee Results: The Attendee Results would likely reflect a mix of interest, curiosity, optimism, ethical considerations, regulatory questions, and discussions about the practical implications of using CRISPR for anxiety treatment. The presentation would likely spark further conversations and exploration into the potential benefits and challenges of this innovative approach.
Related Speakers View all
Michael Rafii
Professor, Medical Director, Alzheimer's & Down Synd...
|
|
Robert P. Friedland MD
Clinical & Research Neurologist; Expert in Brain Dis...
|
|
Marie Bernard
Deputy Director of the National Institute on Aging a...
|
|
Linda Partridge
Director, UCL's Institute of Healthy Ageing; Foundin...
|
|
Richard Isaacson
Director of Research, Parkinson's & Alzheimer's Rese...
|
|
Rudolph E. Tanzi
Alzheimer's Disease Researcher; Professor of Neurolo...
|
|
Neelum T. Aggarwal, MD
Neurologist, Rush Alzheimer's Disease Center
|
|
Dr. James Weinstein
Senior Vice President of Microsoft Healthcare; Visit...
|
|
T.J. Hills
Best-Selling Author, Breast Cancer Prevention & Wome...
|
|
Alice Berger, Ph.D.
Geneticist, Lung Cancer Researcher & Associate Profe...
|
|
Peter Bulova
Down Syndrome Speaker & Researcher; Associate Profes...
|
|
Kimberly Noble
Neuroscientist & Pediatrician; Director of the Neuro...
|
|
Yvonne van Amerongen
Founder of The Hogewey Dementia Village & Retired Se...
|
|
Allan Levey
Chair of the Department of Neurology & Director of t...
|
|
Patrick Brannelly
CEO at The 10,000 Brains Project
|
|
Lisa Miller
Bestselling Author & Psychology Professor at Columbi...
|
|
Tony Attwood
British Psychologist Considered One of the Foremost ...
|
|
Andrew Huberman
Neuroscientist & Professor at Stanford University; H...
|
|
Dr. John DenBoer
Clinical Neuropsychologist, Expert Speaker in Alzhei...
|
|
Roberta Brinton
Director, Center for Innovation in Brain Science
|